scholarly journals Possible role of highly activated mucosal NK cells against viral respiratory infections in children undergoing haematopoietic stem cell transplantation

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Maria Vela ◽  
Teresa del Rosal ◽  
Antonio Pérez-Martínez ◽  
Jaime Valentín ◽  
Inmaculada Casas ◽  
...  

AbstractInfection is the leading cause of non-relapse-related mortality after allogeneic haematopoietic stem cell transplantation (HSCT). Altered functions of immune cells in nasal secretions may influence post HSCT susceptibility to viral respiratory infections. In this prospective study, we determined T and NK cell numbers together with NK activation status in nasopharyngeal aspirates (NPA) in HSCT recipients and healthy controls using multiparametric flow cytometry. We also determined by polymerase chain reaction (PCR) the presence of 16 respiratory viruses. Samples were collected pre-HSCT, at day 0, +10, +20 and +30 after HSCT. Peripheral blood (PB) was also analyzed to determine T and NK cell numbers. A total of 27 pediatric HSCT recipients were enrolled and 16 of them had at least one viral detection (60%). Rhinovirus was the most frequent pathogen (84% of positive NPAs). NPAs of patients contained fewer T and NK cells compared to healthy controls (p = 0.0132 and p = 0.120, respectively). Viral PCR + patients showed higher NK cell number in their NPAs. The activating receptors repertoire expressed by NK cells was also higher in NPA samples, especially NKp44 and NKp46. Our study supports NK cells relevance for the immune defense against respiratory viruses in HSCT recipients.

Author(s):  
Sinha Pranay ◽  
Katherine Reifler ◽  
Michael Rossi ◽  
Manish Sagar

Abstract Detection of diverse respiratory viruses in Boston was around 80% lower after practices were instituted to limit COVID-19 spread compared to the same time period during the previous five years. Continuing the strategies that lower COVID-19 dissemination may be useful in decreasing the incidence of other viral respiratory infections.


2021 ◽  
Vol 65 (4) ◽  
Author(s):  
Aartjan J. W. te Velthuis ◽  
Tatiana G. Zubkova ◽  
Megan Shaw ◽  
Andrew Mehle ◽  
David Boltz ◽  
...  

ABSTRACT Infections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commonwealth of Independent States for the treatment of viral respiratory infections, but its clinical efficacy and mode of action are not well understood. In this study, we investigated the efficacy of enisamium in patients aged between 18 and 60 years with confirmed influenza virus and other viral respiratory infections. Enisamium treatment resulted in reduced influenza virus shedding (at day 3, 71.2% in the enisamium group tested negative versus 25.0% in placebo group [P < 0.0001]), faster patient recovery (at day 14, 93.9% in the enisamium group had recovered versus 32.5% in placebo group [P < 0.0001]), and reduced disease symptoms (from 9.6 ± 0.7 to 4.6 ± 0.9 score points in enisamium group versus 9.7 ± 1.1 to 5.6 ± 1.1 score points in placebo group [P < 0.0001]) compared to those in the placebo group. Using mass spectrometry, and cell-based and cell-free viral RNA synthesis assays, we identified a hydroxylated metabolite of enisamium, VR17-04. VR17-04 is capable of inhibiting influenza virus RNA synthesis and is present in plasma of patients treated with enisamium. VR17-04 inhibits the activity of the influenza virus RNA polymerase more potently than its parent compound. Overall, these results suggest that enisamium is metabolized in humans to an inhibitor of the influenza virus RNA polymerase that reduces viral shedding and improves patient recovery in influenza patients. (This study has been registered at ClinicalTrials.gov under identifier NCT04682444.)


Author(s):  
Amreeta Dhanoa ◽  
Chin Fang Ngim ◽  
Nor’azim Mohd Yunos ◽  
Syed M. Tupur Husain ◽  
Lian Yih Pong ◽  
...  

This study explored the contribution of viral respiratory infections (VRIs) in dengue-like illness (DLI) patients and their distinguishing clinicolaboratory parameters. Two hundred DLI patients were prospectively recruited (1 July–1 October 2019) from a community clinic in Southern Malaysia. Patients ≥18 years with acute fever and fulfilling the WHO criteria of probable dengue were recruited. They underwent blood testing: blood counts, rapid dengue tests (nonstructural antigen-1/IgM) and polymerase chain reaction (PCR) for dengue, Zika, chikungunya, and Leptospira. Nasopharyngeal swabs (NPSs) were collected for FilmArray®RP2plus testing. From the 200 NPSs, 58 respiratory viruses (RVs) were detected in 54 patients. Of the 96 dengue-confirmed cases, 86 had dengue mono-infection, and 10 were coinfected with RVs. Of the 104 nondengue, 44 were RV positive and 4 Leptospira positive. Zika and chikungunya virus were not detected. Overall, the etiological diagnosis was confirmed for 72% of patients. Clinicolaboratory parameters were compared between dengue mono-infection and VRI mono-infection. Patients with coinfections were excluded. Multiple logistic regression showed that recent household/neighborhood history of dengue (adjusted odds ratio [aOR]: 5.9, 95% CI = 1.7–20.7), leukopenia (aOR: 12.5, 95% CI = 2.6–61.4) and thrombocytopenia (aOR: 5.5, 95% CI = 1.3–23.0) predicted dengue. Inversely, rhinorrhoea (aOR: 0.1, 95% CI = 0.01–0.3) and cough (aOR: 0.3, 95% CI = 0.1–0.9) favored VRI. Thus, VRIs comprise many infections diagnosed initially as DLIs. Early clinicolaboratory parameters can guide physicians screen patients for further testing.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2231-2231
Author(s):  
Bergerson Rachel ◽  
Robin Williams ◽  
Hongbo Wang ◽  
Ryan Shanley ◽  
Gretchen Hoff ◽  
...  

Abstract Previously we demonstrated that following dUCBT, increased absolute lymphocyte (ALC) counts early are associated with improved disease free survival (DFS) (Burke, BBMT, 2011). Considering that a significant proportion of the lymphocytes at this time point are NK cells, we hypothesized that higher NK cell counts would be associated with improved transplant outcomes. We further hypothesized that patients with higher NK numbers would have more mature NK cells with increased NK function (cytotoxicity and cytokine production). To test this hypothesis we used a cohort of dUCBTpatients (n=111, separate from Burke, BBMT, 2011) and examined the number of NK cells (CD3-CD56+) in the peripheral blood after dUCBT. Patients were stratified into low (<50 NK cells/mm3), medium (50-120 NK cells/mm3), and high (>120 NK cells/mm3) groups based on absolute NK counts at D+28. The 3 patient groups did not vary based on age, gender, conditioning intensity, degree of HLA mismatch, UCB cell dose or CMVserostatus/reactivation. As shown in Figure 1, in multiple variate regression analysis, patients with low NK cell numbers experienced significantly lower DFS (HR=1.96, 95% CI: 1.02-3.77, p=0.04) (Fig 1A). There was a trend toward higher non-relapse mortality (NRM) in the low group (41% vs. 26% vs. 18% for low, medium, and high NK groups; p=0.08, Fig 1B), but no difference in relapse or aGVHD (Fig 1C and D). We used a multicolor FACS panel that includes a lineage cocktail (CD14, 19 and 3), CD56, CD117, NKG2A, KIR cocktail and CD57, which allowed us to classify the circulating D+28 NK cells into stage III, IV, V and stage VI NK cells. Interestingly, between the three groups, the proportions of NK cells in the various developmental stages did not differ significantly. We next tested the D+28 NK functionality upon a 4 hr.coculture with K562 cells, by staining NK cells for intracellular cytokines (IFN-g, TNF-a) and degranulation (CD107a). Although we tested a considerable number of patients (n=69), there was no difference in any of the three measures of NK functionality between the three patient groups, but all 3 measures were significantly lower than healthy controls. Considering that IL-15 is a key cytokine that drives NK cell maturation proliferation, and survival we tested the 3dUCBT groups for differences in serum IL-15 concentrations, but found no differences (Fig 2A). Given that the groups differed in cell numbers, we used Ki67 staining to assess whether the D+28 NK cells were differentially in cell cycle and undergoing proliferation. While the percentage of Ki67+ NK cells was significantly higher than controls, the 3 patient groups did not significantly differ from one another. We next tested the cells for the response to IL-15 stimulation. To do this, D+28cryoperserved PBMCs were thawed and rested overnight in media without cytokines. The next morning, PBMCs were stimulated with 0.2 ng of IL-15 for 15 min and the NK cells were assessed for the phosphorylation of STAT5 by FACS. Patients with low numbers of NK cells at D+28 had a defect in IL-15 signaling as demonstrated by a lower percentage of NK cells with p-STAT5, compared to patients with high NK cells (Fig 2A, 26% vs 37%, p=0.04). Many signals, including IL-15 drive the expression of key transcription factors includingTbet andEomes, which control NK cell development and functionality. To investigate the expression of these we used multicolor FACS. For T-bet, there was no difference in the mean fluorescent intensity (MFI) or percent expression between patients with either low or high NK cells at D+28 or healthy controls (Fig 2C). In contrast, patients with high numbers of NK cells at D+28 showed significantly moreEomes (by MFI) than patients with low NK numbers (Figure 2D, 675 vs 552, p=0.025). Therewas also a significantly higher proportion of NK cells expressingEomes in patients with high NK numbers compared to patients with low NK numbers or healthy controls (Figure 2E, 72.5% vs 61.3% vs 42.8%, p < 0.01). Thus, patients with low NK numbers at D+28 afterdUCBT have impaired NKEomes expression. Considering that STAT5 regulates T-bet andEomes, these studies uncover an association between IL-15 andEomes that leads to a reduction in NK cell numbers afterdUCBT which is associated with reduced DFS, likely due to increased NRM. Exogenous, supra-physiological IL-15 early afterdUCBT may overcome this defect and improve transplant outcomes. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Miller: Oxis Biotech Scientific Advisory Board: Membership on an entity's Board of Directors or advisory committees.


2016 ◽  
Vol 144 (10) ◽  
pp. 2064-2076 ◽  
Author(s):  
S. NICKBAKHSH ◽  
F. THORBURN ◽  
B. VON WISSMANN ◽  
J. McMENAMIN ◽  
R. N. GUNSON ◽  
...  

SUMMARYViral respiratory infections continue to pose a major global healthcare burden. At the community level, the co-circulation of respiratory viruses is common and yet studies generally focus on single aetiologies. We conducted the first comprehensive epidemiological analysis to encompass all major respiratory viruses in a single population. Using extensive multiplex PCR diagnostic data generated by the largest NHS board in Scotland, we analysed 44230 patient episodes of respiratory illness that were simultaneously tested for 11 virus groups between 2005 and 2013, spanning the 2009 influenza A pandemic. We measured viral infection prevalence, described co-infections, and identified factors independently associated with viral infection using multivariable logistic regression. Our study provides baseline measures and reveals new insights that will direct future research into the epidemiological consequences of virus co-circulation. In particular, our study shows that (i) human coronavirus infections are more common during influenza seasons and in co-infections than previously recognized, (ii) factors associated with co-infection differ from those associated with viral infection overall, (iii) virus prevalence has increased over time especially in infants aged <1 year, and (iv) viral infection risk is greater in the post-2009 pandemic era, likely reflecting a widespread change in the viral population that warrants further investigation.


2020 ◽  
Author(s):  
Tatiana G. Zubkova ◽  
Aartjan J.W. te Velthuis ◽  
Megan Shaw ◽  
Andrew Mehle ◽  
David Boltz ◽  
...  

AbstractInfections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon®) is an antiviral marketed in countries of the Commonwealth of Independent States for the treatment of viral respiratory infections, but its clinical efficacy and mode of action are not well understood. Here, we investigated the efficacy of FAV00A in patients aged between 18-60 years with confirmed influenza and other viral respiratory infections. FAV00A treatment resulted in reduced influenza virus shedding (at day 3, 71.2% in FAV00A group tested negative versus 25.0% in placebo group, p < 0.0001), faster patient recovery (at day 14, 93.9% in FAV00A group had recovered versus 32.5 % in placebo group, p < 0.0001), and reduced disease symptoms compared to placebo (from 9.6 ± 0.7 to 4.6 ± 0.9 score points in FAV00A group versus 9.7 ± 1.1 to 5.6 ± 1.1 score points in placebo group, p < 0.0001). Using mass-spectrometry, and cell-based and cell-free viral RNA synthesis assays, we identified a hydroxylated metabolite of FAV00A, VR17-04. VR17-04 is capable of inhibiting influenza virus RNA synthesis and present in plasma of patients treated with FAV00A. VR-17-04 inhibits the activity of the influenza virus RNA polymerase more potently than its parent compound. Overall, these results suggest that FAV00A is metabolized in humans to an inhibitor of the influenza virus RNA polymerase that reduces viral shedding and improves patient recovery in influenza patients.Clinical data are available on ClincalTrials.gov under NCT04682444.


Author(s):  
Valentin Sencio ◽  
Marina Gomes Machado ◽  
François Trottein

AbstractBacteria that colonize the human gastrointestinal tract are essential for good health. The gut microbiota has a critical role in pulmonary immunity and host’s defense against viral respiratory infections. The gut microbiota’s composition and function can be profoundly affected in many disease settings, including acute infections, and these changes can aggravate the severity of the disease. Here, we discuss mechanisms by which the gut microbiota arms the lung to control viral respiratory infections. We summarize the impact of viral respiratory infections on the gut microbiota and discuss the potential mechanisms leading to alterations of gut microbiota’s composition and functions. We also discuss the effects of gut microbial imbalance on disease outcomes, including gastrointestinal disorders and secondary bacterial infections. Lastly, we discuss the potential role of the lung–gut axis in coronavirus disease 2019.


Sign in / Sign up

Export Citation Format

Share Document